Is Kringle Pharma, Inc. (4884.T) a Buy, Sell, or Hold?
Kringle Pharma, Inc.
JPX:4884.T
$341 JPY
$10 (3.02%)
- Volume
- 40.1K
- Average Volume
- 462.34K
- Market Capitalization
- $2.75B
- P/E Ratio
- -2.62
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $860.00
- Year Low
- $287.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.79
Industry, Sector & symbol
| Stock Exchange | JPX |
| CEO | Kiichi Adachi |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | 4884.T |
| CUSIP | None |
| CIK | None |
| Web | https://www.kringle-pharma.com |
| Phone | 81 7 2641 8739 |
| Currency | JPY |
| Employees | 17 |
| Country | JP |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.79 |
| Quick Ratio | 4.18 |
| Cash Ratio | 2.34 |
Sales & Book Value
| Annual Sales | $72.22M |
| Price / Sales | 38.11 |
| Cash Flow | 0.00 |
| Price / Cash Flow | 0.00 |
| Price / Book | 2.62 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-133.92 |
| Trailing P/E Ratio | -2.62 |
| PEG Ratio | -2.31 |
| P/E Growth | -2.31 |
| Net Income | $-916.26M |
| Net Margin | -1273.20% |
| Pretax Margin | -1270.76% |
| Return on Equity | -75.65% |
| Return on Assets | -46.28% |
Financials Score
| AltmanZ Score | -0.54 |
| Piotroski Score | 2.00 |
| Working Capital | 1.55B |
| Total Assets | 1.99B |
| Ebit | -914.36M |
| Market Cap | 2.67B |
| Total Liabilities | 1.04B |
Poll Results
About Kringle Pharma, Inc. (JPX:4884.T) Stock
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan. ...
Frequently Asked Questions
-
What is the current Kringle Pharma, Inc. (4884.T) stock price?
-
Kringle Pharma, Inc.(JPX:4884.T) stock price is $341 in the last trading session. During the trading session, 4884.T stock reached the peak price of $860 while $287 was the lowest point it dropped to. The percentage change in 4884.T stock occurred in the recent session was 3.02% while the dollar amount for the price change in 4884.T stock was $10.
-
4884.T's industry and sector of operation?
-
The JPX listed 4884.T is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of 4884.T?
-
Kiichi Adachi | President, Chief Executive Officer & Chairman
Koichi Murakami | Director of Business Administration Dept., Business Management Dept. Manager & Director
Matt Vogelhuber | President of Kringle Pharma USA Inc.
Yoshiyuki Kayano | Director & GM of Quality Assurance Department
Daichika Hayata | GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director -
How many employees does 4884.T have?
-
Number of 4884.T employees currently stands at 17. 4884.T operates from 207 Saito Bio Incubator, Ibaraki, None 567-0085, JP.
-
Link for 4884.T official website?
-
Official Website of 4884.T is: https://www.kringle-pharma.com
-
How do I contact 4884.T?
-
4884.T could be contacted at phone #81 7 2641 8739 and can also be accessed through its website. 4884.T operates from 207 Saito Bio Incubator, Ibaraki, None 567-0085, JP.
-
How many shares of 4884.T are traded daily?
-
The average number of 4884.T shares traded daily for last 3 months was 462.34K.
-
What is the market cap of 4884.T currently?
-
The market value of 4884.T currently stands at $2.75B with its latest stock price at $341